Raymond James analyst Aaron Kessler downgrades Frontdoor (NASDAQ:FTDR) from Outperform to Market Perform.
‘Amid Acquisition Speculation, Cytokinetics CEO Stresses Company Can Launch Heart Drug On Its Own’ – STAT News
https://www.statnews.com/2024/05/17/cytokinetics-robert-blum-stat-breakthrough-summit-west/ As Cytokinetics faces pressure to sell itself to a large pharma company following positive late-stage results of its heart
